UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December 2017
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
Exhibit |
Title |
|
|
99.1 |
News Release Dated December 19, 2017 -
Medicure Announces FDA Approval Received for Prexxartan® |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: December 19, 2017 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure Announces FDA Approval Received for Prexxartan®
WINNIPEG, Dec. 19, 2017 /CNW/ - Medicure Inc. ("Medicure"
or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that Carmel Biosciences, Inc.
("Carmel") has received final approval of its New Drug Application from the US Food and Drug Administration ("FDA")
for Prexxartan® (valsartan) oral solution. The FDA approval of Prexxartan® makes it the first
and only approved oral liquid dosage form of the angiotensin II receptor blocker ("ARB") valsartan in the United States.
Previously, on October 31, 2017, Medicure announced that,
through its subsidiary, Medicure International Inc., it had acquired a license to sell and market Prexxartan® in
the United States and its territories from Carmel for a seven year term, with potential extensions to the term available. The Company
intends to launch the product using its existing commercial sales force and infrastructure with a target commercial launch date
during the first half of 2018.
Additionally, the Company announced that its Board of Directors
has approved the grant of an aggregate of 576,000 stock options to certain directors, officers, employees, management company employees
and consultants of the Company pursuant to its stock option plan. These options, which are subject to the approval of the TSX Venture
Exchange, are set to expire on the fifth anniversary of the date of grant and will be issued at an exercise price of $7.20 per
share.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. cardiovascular
market. The primary focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) in the United
States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit
www.medicure.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
Forward Looking Information: Statements contained in
this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates", "intends",
"expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable
Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively
referred to as "forward-looking statements"). Forward-looking statements, include the target launch date for Prexxartan®
and other new products, estimates, analysis and opinions of management of the Company made in light of its experience and its
perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant
and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other
factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied by such forward-looking statements, and as such,
readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's
future product revenues, stage of development, additional capital requirements, risks associated with the completion and timing
of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual
property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid
technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including,
but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and
other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental
approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations
and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical
trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list
of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise
any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional
discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings
with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk
Factors" section of its Form 20F for the year ended December 31, 2016.
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/December2017/19/c3203.html
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 17:30e 19-DEC-17
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Apr 2023 to Apr 2024